| __timestamp | Celldex Therapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 2652041 |
| Thursday, January 1, 2015 | 33837000 | 2361587 |
| Friday, January 1, 2016 | 35979000 | 4472869 |
| Sunday, January 1, 2017 | 25003000 | 5030957 |
| Monday, January 1, 2018 | 19269000 | 4988941 |
| Tuesday, January 1, 2019 | 15426000 | 5196412 |
| Wednesday, January 1, 2020 | 14456000 | 6652774 |
| Friday, January 1, 2021 | 20488000 | 18418247 |
| Saturday, January 1, 2022 | 27195000 | 24827066 |
| Sunday, January 1, 2023 | 30914000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Celldex's SG&A expenses fluctuated, peaking in 2016 with a 48% increase from 2014, before stabilizing around 2023. Opthea, on the other hand, exhibited a remarkable upward trajectory, with expenses surging by over 1,500% from 2014 to 2023, highlighting aggressive expansion strategies. Notably, 2023 marked a pivotal year where Opthea's expenses surpassed Celldex's, indicating a shift in financial dynamics. Missing data for 2024 suggests potential volatility or strategic shifts. This comparative analysis offers a window into the strategic priorities and operational scales of these biotech firms, providing valuable insights for investors and industry analysts alike.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Celldex Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Neurocrine Biosciences, Inc. and Opthea Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Viatris Inc. vs Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Opthea Limited vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Comparing Innovation Spending: Opthea Limited and Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Opthea Limited vs Iovance Biotherapeutics, Inc.
Amneal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? HUTCHMED (China) Limited or Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Taro Pharmaceutical Industries Ltd. and Celldex Therapeutics, Inc.